Clinical Trials
7
Active:0
Completed:7
Trial Phases
2 Phases
Phase 1:6
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (85.7%)Phase 2
1 (14.3%)Dose Escalation Study of Pazopanib Plus TH-302
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Herbert Hurwitz, MD
- Target Recruit Count
- 50
- Registration Number
- NCT01485042
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
Phase 1
Completed
- Conditions
- Solid TumorMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Herbert Hurwitz, MD
- Target Recruit Count
- 22
- Registration Number
- NCT00920868
- Locations
- 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Duke Univeristy Medical Center, Durham, North Carolina, United States
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Drug: CNTO 95 and avastin
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Herbert Hurwitz, MD
- Target Recruit Count
- 13
- Registration Number
- NCT00888043
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
- First Posted Date
- 2008-01-04
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Herbert Hurwitz, MD
- Target Recruit Count
- 56
- Registration Number
- NCT00586443
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Herbert Hurwitz, MD
- Target Recruit Count
- 50
- Registration Number
- NCT00416494
- Prev
- 1
- 2
- Next
News
No news found